Clinical Trial Update: A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202) [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating SAR444245 in combination with other anticancer therapies for pleural mesothelioma and non-small cell lung cancer has been terminated,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer
• Pleural Mesothelioma

Drugs mentioned

• SAR444245

Snippet

Sponsor: Sanofi | Conditions: Pleural Mesothelioma, Non-small Cell Lung Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-10-02